Gravitor Tablet contains Pyridostigmine 60 mg, a cholinesterase inhibitor primarily indicated for the symptomatic treatment of myasthenia gravis, a neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. Pyridostigmine acts by inhibiting acetylcholinesterase, the enzyme responsible for the breakdown of acetylcholine at the neuromuscular junction, thereby enhancing cholinergic transmission and improving muscle strength. This medication is also utilized in certain cases of post-polio syndrome and as a prophylactic agent against nerve agent poisoning. Gravitor Tablet is administered orally, with dosage individualized based on clinical response and severity of symptoms. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, abdominal cramps, and increased salivation, which are generally mild and dose-dependent. Caution is advised in patients with asthma, cardiovascular diseases, or gastrointestinal obstruction. Pyridostigmine should be used under strict medical supervision, with regular monitoring to optimize therapeutic outcomes and minimize side effects. It is contraindicated in patients with mechanical intestinal or urinary obstruction and known hypersensitivity to the drug. Gravitor Tablet provides an effective means of improving muscle function and quality of life in patients with neuromuscular disorders when used appropriately.